ACAD
Price:
$16.07
Market Cap:
$2.67B
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for...[Read more]
Industry
Biotechnology
IPO Date
2004-05-27
Stock Exchange
NASDAQ
Ticker
ACAD
According to ACADIA Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 84.58. This represents a change of 320.97% compared to the average of 20.09 of the last 4 quarters.
The mean historical PE Ratio of ACADIA Pharmaceuticals Inc. over the last ten years is -26.32. The current 84.58 PE Ratio has changed -32237.51% with respect to the historical average. Over the past ten years (40 quarters), ACAD's PE Ratio was at its highest in in the June 2023 quarter at 878.55. The PE Ratio was at its lowest in in the September 2021 quarter at -46.15.
Average
-26.32
Median
-22.07
Minimum
-83.69
Maximum
-8.35
Discovering the peaks and valleys of ACADIA Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 602.23%
Maximum Annual PE Ratio = -8.35
Minimum Annual Increase = -46.59%
Minimum Annual PE Ratio = -83.69
Year | PE Ratio | Change |
---|---|---|
2023 | -83.69 | 602.23% |
2022 | -11.92 | -46.59% |
2021 | -22.31 | -25.30% |
2020 | -29.87 | 11.59% |
2019 | -26.77 | 220.64% |
2018 | -8.35 | -34.55% |
2017 | -12.76 | 3.60% |
2016 | -12.31 | -43.56% |
2015 | -21.82 | -34.66% |
2014 | -33.39 | -40.85% |
The current PE Ratio of ACADIA Pharmaceuticals Inc. (ACAD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-39.31
5-year avg
-34.91
10-year avg
-26.32
ACADIA Pharmaceuticals Inc.’s PE Ratio is greater than Madrigal Pharmaceuticals, Inc. (-10.23), greater than Viking Therapeutics, Inc. (-61.76), less than Sarepta Therapeutics, Inc. (257.91), greater than Hepion Pharmaceuticals, Inc. (-0.15), greater than PTC Therapeutics, Inc. (-5.05), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), greater than Athira Pharma, Inc. (-0.18), greater than Fortress Biotech, Inc. (-0.71), greater than Cabaletta Bio, Inc. (-2.34), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Akero Therapeutics, Inc. (-8.95), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than Krystal Biotech, Inc. (49.72), greater than Blueprint Medicines Corporation (-26.44),
Company | PE Ratio | Market cap |
---|---|---|
-10.23 | $5.30B | |
-61.76 | $6.00B | |
257.91 | $12.29B | |
-0.15 | $4.20M | |
-5.05 | $2.43B | |
-1.10 | $44.68M | |
-0.18 | $20.81M | |
-0.71 | $40.38M | |
-2.34 | $208.10M | |
-13.55 | $794.69M | |
-6.06 | $549.60M | |
-8.95 | $1.83B | |
-89.36 | $6.57B | |
49.72 | $5.29B | |
-26.44 | $5.47B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ACADIA Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ACADIA Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ACADIA Pharmaceuticals Inc.'s PE Ratio?
How is the PE Ratio calculated for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the highest PE Ratio for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 3-year average PE Ratio for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 5-year average PE Ratio for ACADIA Pharmaceuticals Inc. (ACAD)?
How does the current PE Ratio for ACADIA Pharmaceuticals Inc. (ACAD) compare to its historical average?